18.03.2021 | ASO Author Reflections
ASO Author Reflections: Patient-Derived Tumor Xenografts and Ex Vivo Models Mimic the Clinical Response of Locally Aggressive Tumors to Approved Drug Candidates
verfasst von:
Fan Tang, MD, PhD, Yan Tie, MD, PhD, Xiawei Wei, PhD, Chongqi Tu, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 11/2021
Einloggen, um Zugang zu erhalten
Excerpt
Clinical management of locally aggressive tumors including tenosynovial giant cell tumors (TGCTs), giant cell tumors of bone, and desmoid fibromatosis is challenging due to the high rate of recurrence after surgical resection and lack of systemic therapies,
1 even though signals that contribute to the tumorigenesis and progression of these tumors have been well identified. For example, the CSF1/CSF1R axis represents the typical molecular feature of TGCT and a promising therapeutic target for advanced TGCT.
2 However, the main obstacle to drug validation and development for these tumors is the lack of favorable preclinical translation platforms. …